CRISPR Therapeutics AG (CRSP) Capital Expenditures (2015 - 2026)

CRISPR Therapeutics AG has disclosed Capital Expenditures across 12 years of filings, most recently posting $648000.0 for Q2 2026.

• In Q2 2026, Capital Expenditures rose 453.85% year-over-year to $648000.0; the TTM figure through Jun 2026 stood at $1.7 million (up 118.97% YoY), while the FY2025 annual figure was $914000.0, down 51.92% from the prior year.
• Capital Expenditures came in at $648000.0 for Q2 2026 at CRISPR Therapeutics AG, up from $504000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $15.4 million in Q1 2022 to a low of $74000.0 in Q3 2025.
• Average Capital Expenditures over 5 years is $2.8 million, with a median of $714000.0 recorded in 2024.
• Year-over-year, Capital Expenditures tumbled 89.66% in 2024 and jumped 453.85% in 2026.
• Over 5 years, Capital Expenditures stood at $6.2 million in 2022, then sank by 88.08% to $738000.0 in 2023, then sank by 65.58% to $254000.0 in 2024, then jumped by 103.54% to $517000.0 in 2025, then grew by 25.34% to $648000.0 in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $648000.0 in Q2 2026, $504000.0 in Q1 2026, and $517000.0 in Q4 2025.